Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, has secured approximately $4.6 million in gross proceeds through the exercise of multiple series of warrants. The agreement involves the immediate exercise of Series A, B-1, C-1, D, E, and F warrants for 6,595,000 shares at a reduced price of $0.70 per share.
In exchange for the immediate cash exercise, Calidi will issue new unregistered warrants to purchase up to 6,595,000 shares at $0.70 per share, exercisable after six months with a 5.5-year term. The proceeds will support clinical and pre-clinical programs, operating expenses, and working capital. Ladenburg Thalmann & Co. is serving as the exclusive placement agent.
Calidi Biotherapeutics (NYSE American: CLDI), una societ脿 biotecnologica in fase clinica, ha raccolto circa 4,6 milioni di dollari di proventi lordi tramite l'esercizio di pi霉 serie di warrant. L'accordo prevede l'esercizio immediato dei warrant delle serie A, B-1, C-1, D, E e F per 6.595.000 azioni a un prezzo ridotto di 0,70 dollari per azione.
In cambio dell'esercizio immediato in contanti, Calidi emetter脿 nuovi warrant non registrati per acquistare fino a 6.595.000 azioni a 0,70 dollari per azione, esercitabili dopo sei mesi e con una durata di 5,5 anni. I proventi sosterranno programmi clinici e pre-clinici, spese operative e capitale circolante. Ladenburg Thalmann & Co. agisce come agente di collocamento esclusivo.
Calidi Biotherapeutics (NYSE American: CLDI), una empresa biotecnol贸gica en etapa cl铆nica, ha asegurado aproximadamente 4.6 millones de d贸lares en ingresos brutos mediante el ejercicio de varias series de warrants. El acuerdo implica el ejercicio inmediato de los warrants de las Series A, B-1, C-1, D, E y F para 6,595,000 acciones a un precio reducido de 0.70 d贸lares por acci贸n.
Como contraprestaci贸n por el ejercicio inmediato en efectivo, Calidi emitir谩 nuevos warrants no registrados para comprar hasta 6,595,000 acciones a 0.70 d贸lares por acci贸n, ejercibles despu茅s de seis meses y con un plazo de 5.5 a帽os. Los ingresos apoyar谩n programas cl铆nicos y precl铆nicos, gastos operativos y capital de trabajo. Ladenburg Thalmann & Co. act煤a como agente de colocaci贸n exclusivo.
Calidi Biotherapeutics (NYSE American: CLDI)電� 鞛勳儊 雼硠 氚旍澊鞓ろ厡韥� 須岇偓搿�, 鞐煬 鞁滊Μ歃堨潣 鞗岆煱韸� 頄夓偓搿� 鞎� 460毵� 雼煬鞚� 齑� 靾橃澋鞚� 頇曤炒頄堨姷雼堧嫟. 鞚措矆 瓿勳暯鞚� 鞁滊Μ歃� A, B-1, C-1, D, E, F 鞗岆煱韸鸽ゼ 歃夓嫓 頄夓偓頃橃棳 6,595,000欤�毳� 欤茧嫻 0.70雼煬鞚� 頃犾澑霅� 臧�瓴�鞐� 毵れ瀰頃橂姅 雮挫毄鞛呺媹雼�.
歃夓嫓 順勱笀 頄夓偓鞐� 雽�頃� 雽�臧�搿�, Calidi電� 6臧滌洈 頉� 頄夓偓 臧�電ロ晿氅� 5.5雲� 毵岅赴鞚� 欤茧嫻 0.70雼煬鞐� 斓滊寑 6,595,000欤�毳� 毵れ垬頃� 靾� 鞛堧姅 鞁犼窚 氙鸽摫搿� 鞗岆煱韸鸽ゼ 氚滍枆頃� 鞓堨爼鞛呺媹雼�. 靾橃澋旮堨潃 鞛勳儊 氚� 鞝勳瀯靸� 頂勲攴鸽灗, 鞖挫榿牍� 氚� 鞖挫爠鞛愲掣鞐� 靷毄霅╇媹雼�. Ladenburg Thalmann & Co.臧� 霃呾爯 氚办箻 雽�頄夓偓搿� 頇滊彊頃橁碃 鞛堨姷雼堧嫟.
Calidi Biotherapeutics (NYSE American : CLDI), une soci茅t茅 biotechnologique en phase clinique, a obtenu environ 4,6 millions de dollars de produit brut gr芒ce 脿 l鈥檈xercice de plusieurs s茅ries de bons de souscription (warrants). L鈥檃ccord concerne l鈥檈xercice imm茅diat des warrants des s茅ries A, B-1, C-1, D, E et F pour 6 595 000 actions 脿 un prix r茅duit de 0,70 dollar par action.
En 茅change de cet exercice imm茅diat en num茅raire, Calidi 茅mettra de nouveaux warrants non enregistr茅s permettant d鈥檃cheter jusqu鈥櫭� 6 595 000 actions au prix de 0,70 dollar par action, exer莽ables apr猫s six mois et valables pendant 5,5 ans. Les fonds serviront 脿 soutenir les programmes cliniques et pr茅cliniques, les d茅penses op茅rationnelles et le fonds de roulement. Ladenburg Thalmann & Co. agit en tant qu鈥檃gent de placement exclusif.
Calidi Biotherapeutics (NYSE American: CLDI), ein biotechnologisches Unternehmen in der klinischen Phase, hat durch die Aus眉bung mehrerer Serien von Warrants rund 4,6 Millionen US-Dollar Bruttoerl枚s erzielt. Die Vereinbarung umfasst die sofortige Aus眉bung der Serien A, B-1, C-1, D, E und F Warrants f眉r 6.595.000 Aktien zu einem reduzierten Preis von 0,70 US-Dollar pro Aktie.
Im Gegenzug f眉r die sofortige Bareinl枚sung wird Calidi neue nicht registrierte Warrants ausgeben, um bis zu 6.595.000 Aktien zu je 0,70 US-Dollar zu kaufen, aus眉bbar nach sechs Monaten mit einer Laufzeit von 5,5 Jahren. Die Erl枚se dienen der Unterst眉tzung klinischer und pr盲klinischer Programme, Betriebskosten und des Umlaufkapitals. Ladenburg Thalmann & Co. fungiert als exklusiver Platzierungsagent.
- Secured $4.6 million in immediate gross proceeds through warrant exercise
- New warrants issued with 5.5-year term provide potential for additional future funding
- Proceeds will advance clinical and pre-clinical programs
- Warrants exercised at reduced price of $0.70, indicating potential discount to market value
- Dilutive impact from issuance of 6,595,000 new shares
- Additional dilution possible from new warrant issuance of 6,595,000 shares
Insights
Calidi secures $4.6M through warrant exercise at discounted price, extending cash runway while diluting shareholder value.
Calidi Biotherapeutics has secured approximately
The structure of this deal is particularly telling. By offering a reduced exercise price on existing warrants and issuing new warrants with a 5.5-year term, Calidi is effectively incentivizing early capital infusion while extending future financing options. This approach typically indicates a company prioritizing near-term cash needs over potential long-term dilution concerns. The
The disclosed use of proceeds - advancing clinical/pre-clinical programs and covering operating expenses - indicates that this funding is primarily intended to extend Calidi's operational runway rather than for strategic expansion. For a clinical-stage biotech without commercial products, this type of bridge financing is common but highlights the ongoing capital-intensive nature of drug development. This warrant exercise provides necessary funding to continue operations while the company works toward potentially more significant clinical milestones that could support higher-valuation financing rounds in the future.
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (鈥淐alidi鈥� or the 鈥淐ompany鈥�) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series A, Series B-1, Series C-1, Series D, Series E and Series F Warrants (the 鈥淓xisting Warrants鈥�) to purchase up to an aggregate of 6,595,000 shares of the Company鈥檚 common stock at a reduced exercise price of
Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.
In consideration for the immediate exercise of the Existing Warrants for cash, the Company will issue new unregistered warrants to purchase up to 6,595,000 shares of common stock. The new warrants will have an exercise price of
The offering is expected to close on or about July 10, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering to advance its clinical and pre-clinical programs and for continuing operating expenses and working capital.
The new warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 鈥淎ct鈥�), and Regulation D promulgated thereunder and, along with the shares underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the new warrants issued in the private placement and the shares underlying the new warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company's proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.
The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.
Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit聽.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the 鈥渟afe harbor鈥� provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as 鈥渁nticipates,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntends,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減ossible,鈥� 鈥減otential,鈥� 鈥減redicts,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渢owards,鈥� 鈥渨ould鈥� as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward looking statements include, but are not limited to, statements concerning use of proceeds from the offering, that the closing of offering will occur or will occur on the anticipated closing date, upcoming key milestones, planned clinical trials, and statements relating to the safety and efficacy of Calidi鈥檚 therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi鈥檚 current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled 鈥淩isk Factors鈥� and 鈥淐autionary Note Regarding Forward-Looking Statements鈥� in the Company鈥檚 Form 10-K filed on March 31, 2025 and Form 10-Q filed on May 14, 2025. These reports may be amended or supplemented by other reports we file with the SEC from time to time.
Contacts:
For Investors and Media:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
FAQ
How much funding did Calidi Biotherapeutics (CLDI) raise through warrant exercise?
What is the exercise price of CLDI's new warrants and when can they be exercised?
How many new shares will be issued from CLDI's warrant exercise?
How will Calidi Biotherapeutics use the proceeds from the warrant exercise?
Who is the placement agent for CLDI's warrant exercise transaction?
